After discontinuing its only clinical-stage candidate, ADC Therapeutics announced the closure of its UK R&D site and a 30% workforce reduction. The restructuring focuses resources on approved cancer therapies and prioritized preclinical programs. These actions reflect recent clinical setbacks and financial pressures in the neuro-oncology biotech sector.